medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2009, Number 3

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2009; 22 (3)

Clinic oncology, genomics and epigenomics on bronchogenic cancer. Part I

Cerecedo-Zapata CM, Limón RD, Gonzaga PR, Serrano-Ramírez R, Álvarez MA, Téllez BJL, Ávila-Moreno F

Language: Spanish
References: 57
Page: 217-229
PDF size: 106.22 Kb.


ABSTRACT

Bronchogenic carcinoma remains a serious public health problem in Mexico and worldwide, representing the first cause of death due to malignant neoplasms in both genders. This situation is motivated by the lack of an early diagnosis due to the low specificity of clinical data and the low sensitivity of diagnostic methods in early stages. Lung carcinomas are divided in two groups: small cell lung carcinomas and non-small cell lung carcinomas, the last being the most frequent type comprising 80% cases. Associated risk factors include: tobacco habit, exposure to asbestos, radiation, polycyclic hydrocarbons, PM2.5, PM10, etc., as well as protective factors such as a high ingestion of boron, hormone replacement therapy and abundant intake of fruits and vegetables, though these last are still in controversy. With relation to the beginning of chemotherapy and/or radiotherapy, the patient must be staged according to TNM classification, where two groups are distinguished, those beneficed by surgery and those with unresectable tumors. Although several internationally described therapeutic schemes exist, until now they offer no significant advantages over those recommended by the American Society of Clinical Oncology. Nevertheless, there are encouraging results from basic and clinical research that through massive genome analysis have identified genetic and epigenetic markers associated with the prediction of response to therapy, survival, relapses, etc., and that await to be accepted as guiders for the treatment of bronchogenic carcinoma.


REFERENCES

  1. Reynales-Shigematsu LM, Juárez-Márquez SA, Valdés-Salgado R. Costos de atención médica atribuibles al tabaquismo en el IMSS, Morelos. Salud Pública Mex 2005;47:451-457.

  2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.

  3. Alva LLF, Corcho VA, García-Sancho FC, et ál. Epidemiología del cáncer pulmonar en México; hallazgos por imagen. Rev Inst Nal Enf Resp Mex 2003; 16:197-204.

  4. Nikliñski J, Nikliñska W, Laudanski J, Chyczewska E, Chyczewski L. Prognostic molecular markers in non-small cell lung cancer. Lung Cancer 2001;34 Suppl 2:S53-S58.

  5. Registro Histopatológico de Neoplasias Malignas. Compendio: mortalidad y morbilidad 2001. Secretaría de Salud, Epidemiología. 2001. Fecha de Consulta: 10 de agosto, 2009. Accesible en: http://www.dgepi. salud.gob.mx/diveent/RHNM.htm

  6. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers a different disease. Nat Rev Cancer 2007; 7:778-790.

  7. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-1068.

  8. Ramírez CE, Cicero SR, Zúñiga CG, Novelo V, Navarro F, Casanova JM. El cáncer broncogénico en el Hospital General de México. Estudio de dos décadas. Salud Pública Mex 1995;37:155-161.

  9. Medina-Morales F, Salazar-Flores M. Frecuencia y patrón cambiante del cáncer pulmonar en México. Salud Pública Mex 2000;42:333-336.

  10. Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. Int J Epidemiol 2007;36:1048-1059.

  11. World Health Organization. WHO Global Infobase. Fecha de consulta: 18 de agosto, 2009. Accesible en: http://www.who.int/infobase/cancer.aspx

  12. Jemal A, Siegel R, Ward E, et ál. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.

  13. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.

  14. Stewart BW, Kleihues P, editors. World Cancer Report 2003. International Agency for Research on Cancer Press. Lyon, France. 2003. Accesible en: www.who.int/oral_health/media/en/orh_report03_en.pdf

  15. Instituto Nacional de Estadística y Geografía. Boletín de estadísticas vitales, 2007. Fecha de consulta: 21 de septiembre, 2009. Accesible en: www.inegi.org.mx/ prod_serv/contenidos/espanol/bvinegi/productos/continuas/vitales/boletin/2007/boletin_vitales_07.pdf

  16. Sistema Nacional de Información en Salud. Información de mortalidad 2000-2005. Fecha de consulta: 15 de agosto, 2009. Accesible en: http://www.sinais.salud. gob.mx/mortalidad/index.html

  17. Franco-Marina F, Villalba-Caloca J. La epidemia de cáncer pulmonar en México. Rev Inst Nal Enf Resp Mex 2001;14:207-214.

  18. Tovar-Guzmán VJ, López-Antuñano FJ, Rodríguez-Salgado N. Tendencias de la mortalidad por cáncer pulmonar en México, 1980-2000. Rev Panam Salud Pública 2005;17:254-262.

  19. Jemal A, Tiwari RC, Murray T, et ál; American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.

  20. Harpole DH Jr, Herndon JE 2nd, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995;55:51-56.

  21. Medina MF, Salazar FM, García-Sancho MC, Franco MF. Epidemiología descriptiva del cáncer pulmonar en el Instituto Nacional de Enfermedades Respiratorias, México, 1997-2000. Rev Inst Nal Enf Resp Mex 2002; 15:149-152.

  22. Harvey RG. Polycyclic aromatic hydrocarbons: chemistry and carcinogenicity. Cambridge (UK): Cambridge University Press; 1991.

  23. Omenn GS, Goodman GE, Thornquist MD, et ál. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996;88:1550-1559.

  24. Wright ME, Park Y, Subar AF, et ál. Intakes of fruit, vegetables, and specific botanical groups in relation to lung cancer risk in the NIH-AARP Diet and Health Study. Am J Epidemiol 2008;168:1024-1034.

  25. Mahabir S, Spitz MR, Barrera SL, Dong YQ, Eastham C, Forman MR. Dietary boron and hormone replacement therapy as risk factors for lung cancer in women. Am J Epidemiol 2008;167:1070-1080.

  26. Tang N, Wu Y, Ma J, Wang B, Yu R. Coffee consumption and risk of lung cancer: a meta-analysis. Lung Cancer 2009;67:17-22.

  27. Kabat GC, Kim M, Hunt JR, Chlebowski RT, Rohan TE. Body mass index and waist circumference in relation to lung cancer risk in the Women’s Health Initiative. Am J Epidemiol 2008;168:158-169.

  28. Knaapen AM, Borm PJ, Albrecht C, Schins RP. Inhaled particles and lung cancer. Part A: mechanisms. Int J Cancer 2004;109:799-809.

  29. Sánchez-Pérez Y, Chirino YI, Osornio-Vargas AR, et ál. DNA damage response of A549 cells treated with particulate matter (PM10) of urban air pollutants. Cancer Lett 2009;278:192-200.

  30. Sierra-Vargas MP, Guzmán-Grenfell AM, Blanco-Jiménez S, et ál. Airborne particulate matter PM2.5 from Mexico City affects the generation of reactive oxygen species by blood neutrophils from asthmatics: an in vitro approach. J Occup Med Toxicol 2009;4:17. Publisher online: doi: 10.1186/1745-6673-4-17.

  31. Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F; American College of Chest Physicians. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003;123(1 Suppl):147S-156S.

  32. Pfister DG, Johnson DH, Azzoli CG, et ál; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.

  33. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999;341:1198-205.

  34. Baumgartner FJ. Cardiothoracic surgery. 3rd. ed. USA: Landes Bioscience; 2003.p.195-222.

  35. Goldstraw P, Crowley J, Chansky K, et ál; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714.

  36. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Piagnon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.

  37. Shepherd FA, Dancey J, Ramlau R, et ál. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.

  38. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et ál; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.

  39. Herbst RS, Prager D, Hermann R, et ál; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.

  40. Sandler A, Gray R, Perry MC, et ál. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.

  41. Rapp E, Pater JL, Willan A, et ál. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633-641.

  42. Cullen MH, Billingham LJ, Woodroffe CM, et ál. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-3194.

  43. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs. supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994;106:861-865.

  44. Schiller JH, Harrington D, Belani CP, et ál; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.

  45. Scagliotti GV, Parikh P, von Pawel J, et ál. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.

  46. Hanna N, Shepherd FA, Fossella FV, et ál. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.

  47. Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K; SIGN Study Group. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006;17:401-409.

  48. Cardona AF, Reveiz L, Ospina EG, Ospina V, Yepes A. Braquiterapia endobronquial paliativa para el cáncer de pulmón de células no pequeñas. En: La Biblioteca Cochrane Plus. Número 2, 2008. Fecha de consulta: 12 de agosto, 2009. Accesible en: http://mrw.interscience. wiley.com/Cochrane/ clsysrev/articles/CD004284/frame. html

  49. Sos ML, Michel K, Zander T, et ál. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009;119:1727-1740.

  50. Slamon DJ, Leyland-Jones B, Shak S, et ál. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.

  51. Druker BJ, Sawyers CL, Kantarjian H, et ál. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.

  52. Paez JG, Jänne PA, Lee JC, et ál. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.

  53. Lau SK, Boutros PC, Pintilie M, et ál. Three-gene prognostic classifier for early-stage non small cell lung cancer. J Clin Oncol 2007;25:5562-5569.

  54. Weir BA, Woo MS, Getz G, et ál. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-898.

  55. Beer DG, Kardia SL, Huang CC, et ál. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-824.

  56. Chen JJ, Peck K, Hong TM, et ál. Global analysis of gene expression in invasion by a lung cancer model. Cancer Res 2001;61:5223-5230.

  57. Chen HY, Yu SL, Chen CH, et ál. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.




2020     |     www.medigraphic.com